Willkie represents Vatera Healthcare Partners as part of the investment consortium in the acquisition of a controlling stake in Alvogen, a high-growth pharmaceutical company.
On June 22, it was announced that a consortium of investors led by CVC Capital Partners and including Willkie client Vatera Healthcare Partners and Singapore-based investment company Temasek have acquired a controlling stake in Alvogen, the high-growth pharmaceutical company. The stake has been acquired from Pamplona Capital Management. Aztiq Pharma, the investment vehicle led by Alvogen CEO Robert Wessman, will retain a significant stake and Pamplona will also retain a small stake following the transaction. Mr. Wessman will continue to serve as the company’s CEO.
Alvogen is an international, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter (OTC) brands and biosimilar products. The company has commercial operations in 35 countries with 2,300 employees and operates five manufacturing and development hubs. CVC is a European private equity firm.
Vatera is a New York City-based investment group focused on taking active positions in biotech/pharmaceutical firms and products. Vatera’s objective is to identify and develop best-in-class therapies to treat unmet or underserved medical needs. Willkie previously represented Pearl Therapeutics and its shareholders, led by Vatera, in Pearl’s $1.15 billion sale to AstraZeneca.
The current deal was handled by partners Gordon Caplan, Sean Ewen and Christopher Peters and associates Robert Rizzo, Katharine Donaldson and Susannah Ostlund.